Pharming Group (NASDAQ:PHAR) Shares Gap Down – What’s Next?

Shares of Pharming Group (NASDAQ:PHAR) gapped down prior to trading on Friday . The stock had previously closed at $8.93, but opened at $8.62. Pharming Group shares last traded at $8.63, with a volume of 300 shares.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PHAR. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target on the stock. Oppenheimer raised their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research note on Friday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday.

Pharming Group Stock Down 0.3 %

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a market cap of $605.75 million, a PE ratio of -34.25 and a beta of -0.10. The business’s 50-day simple moving average is $8.90 and its 200 day simple moving average is $8.62.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The business had revenue of $92.70 million for the quarter, compared to analysts’ expectations of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, equities research analysts expect that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.